|
1
|
Weetman AP: Graves' disease. N Engl J Med.
343:1236–1248. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abraham-Nordling M, Törring O, Hamberger
B, Lundell G, Tallstedt L, Calissendorff J and Wallin G: Graves'
disease: A long-term quality-of-life follow up of patients
randomized to treatment with antithyroid drugs, radioiodine, or
surgery. Thyroid. 15:1279–1286. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Estcourt S, Vaidya B, Quinn A and Shepherd
M: The impact of thyroid eye disease upon patients' wellbeing: A
qualitative analysis. Clin Endocrinol (Oxf). 68:635–639. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bahn RS: Graves' ophthalmopathy. N Engl J
Med. 362:726–738. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burch HB and Wartofsky L: Graves'
ophthalmopathy: Current concepts regarding pathogenesis and
management. Endocr Rev. 14:747–793. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Minakaran N and Ezra DG: Rituximab for
thyroid-associated ophthalmopathy. Cochrane Database Syst Rev.
5:CD0092262013.PubMed/NCBI
|
|
7
|
Reff ME, Carner K, Chambers KS, Chinn PC,
Leonard JE, Raab R, Newman RA, Hanna N and Anderson DR: Depletion
of B cells in vivo by a chimeric mouse human monoclonal antibody to
CD20. Blood. 83:435–445. 1994.PubMed/NCBI
|
|
8
|
Tsokos GC: B cells, be gone-B-cell
depletion in the treatment of rheumatoid arthritis. N Engl J Med.
350:2546–2548. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shen S, Chan A, Sfikakis PP, Hsiu Ling AL,
Detorakis ET, Boboridis KG and Mavrikakis I: B-cell targeted
therapy with rituximab for thyroid eye disease: Closer to the
clinic. Surv Ophthalmol. 58:252–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mourits MP, Koornneef L, Wiersinga WM,
Prummel MF, Berghout A and van der Gaag R: Clinical criteria for
the assessment of disease activity in Graves' ophthalmopathy: A
novel approach. Br J Ophthalmol. 73:639–644. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wiersinga WM, Smit T, Schuster-Uittenhoeve
AL, van der Gaag R and Koornneef L: Therapeutic outcome of
prednisone medication and of orbital irradiation in patients with
Graves' ophthalmopathy. Ophthalmologica. 197:75–84. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Edwards JC, Szczepanski L, Szechinski J,
Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM and Shaw T:
Efficacy of B-cell-targeted therapy with rituximab in patients with
rheumatoid arthritis. N Engl J Med. 350:2572–2581. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han R and Smith TJ: T helper type 1 and
type 2 cytokines exert divergent influence on the induction of
prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in
orbital fibroblasts: Implications for the pathogenesis of
thyroid-associated ophthalmopathy. Endocrinology. 147:13–19. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krassas GE, Gogakos A and Boboridis K:
Corticosteroids in the medical treatment of thyroid ophthalmopathy:
When and how? Somatostatin analogues: Where we stand today. Pediatr
Endocrinol Rev. 7(Suppl 2): S204–S209. 2010.
|
|
15
|
Rajendram R, Bunce C, Lee RW and Morley
AM: Orbital radiotherapy for adult thyroid eye disease. Cochrane
Database Syst Rev. 7:CD0071142012.PubMed/NCBI
|
|
16
|
Boboridis KG and Bunce C: Surgical orbital
decompression for thyroid eye disease. Cochrane Database Syst Rev.
12:CD0076302011.PubMed/NCBI
|
|
17
|
Salvi M, Vannucchi G, Campi I, Currò N,
Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, et
al: Treatment of Graves' disease and associated ophthalmopathy with
the anti-CD20 monoclonal antibody rituximab: An open study. Eur J
Endocrinol. 156:33–40. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bahn RS: Clinical review 157:
Pathophysiology of Graves' ophthalmopathy: The cycle of disease. J
Clin Endocrinol Metab. 88:1939–1946. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Valyasevi RW, Harteneck DA, Dutton CM and
Bahn RS: Stimulation of adipogenesis, peroxisome
proliferator-activated receptor-gamma (PPARgamma), and thyrotropin
receptor by PPARgamma agonist in human orbital preadipocyte
fibroblasts. J Clin Endocrinol Metab. 87:2352–2358. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps
RP and Smith TJ: Activation of human orbital fibroblasts through
CD40 engagement results in a dramatic induction of hyaluronan
synthesis and prostaglandin endoperoxide H synthase-2 expression.
Insights into potential pathogenic mechanisms of thyroid-associated
ophthalmopathy. J Biol Chem. 273:29615–29625. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
El FD, Nielsen CH, Bonnema SJ, Hasselbalch
HC and Hegedüs L: B lymphocyte depletion with the monoclonal
antibody rituximab in Graves' disease: A controlled pilot study. J
Clin Endocrinol Metab. 92:1769–1772. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Heemstra KA, Toes RE, Sepers J, Pereira
AM, Corssmit EP, Huizinga TW, Romijn JA and Smit JW: Rituximab in
relapsing Graves' disease, a phase II study. Eur J Endocrinol.
159:609–615. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brent GA: Clinical practice. Graves'
disease. N Engl J Med. 358:2594–2605. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hasselbalch HC: B-cell depletion with
rituximab-a targeted therapy for Graves' disease and autoimmune
thyroiditis. Immunol Lett. 88:85–86. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang SH and Baker JJ: Targeting B cells in
Graves' disease. Endocrinology. 147:4559–4560. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Salvi M, Vannucchi G, Campi I, Currò N,
Simonetta S, Covelli D, Pignataro L, Guastella C, Rossi S, Bonara
P, et al: Rituximab treatment in a patient with severe
thyroid-associated ophthalmopathy: Effects on orbital lymphocytic
infiltrates. Clin Immunol. 131:360–365. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Khanna D, Chong KK, Afifiyan NF, Hwang CJ,
Lee DK, Garneau HC, Goldberg RA, Darwin CH, Smith TJ and Douglas
RS: Rituximab treatment of patients with severe,
corticosteroid-resistant thyroid-associated ophthalmopathy.
Ophthalmology. 117:133.e2–139.e2. 2010. View Article : Google Scholar
|
|
28
|
Mitchell AL, Gan EH, Morris M, Johnson K,
Neoh C, Dickinson AJ, Perros P and Pearce SH: The effect of B cell
depletion therapy on anti-TSH receptor antibodies and clinical
outcome in glucocorticoid-refractory Graves' orbitopathy. Clin
Endocrinol (Oxf). 79:437–442. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Salvi M, Vannucchi G, Currò N, Campi I,
Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone
S and Beck-Peccoz P: Efficacy of B-cell targeted therapy with
rituximab in patients with active moderate-severe Graves'
orbitopathy: A randomized controlled study. J Clin Endocrinol
Metab. 100:422–431. 2015. View Article : Google Scholar : PubMed/NCBI
|
